Vimentin is a type III intermediate filament protein widely expressed in cells of mesenchymal origin and dynamically regulated during epithelial–mesenchymal transition (EMT). Detection of vimentin by immunohistochemistry (IHC) on formalin-fixed paraffin-embedded (FFPE) tissue is a well-established method to document mesenchymal differentiation, assist in lineage assignment, and complement epithelial markers in challenging diagnostic scenarios. Anti-Vimentin antibodies that are CE marked for in-vitro diagnostic (CE/IVD) use provide validated reagents for clinical pathology laboratories.

Diagnostic utility in gynecological pathology

In gynecologic practice, vimentin IHC has proven value as part of an immunopanel to help determine site of origin and differentiation:

• Endometrial vs endocervical adenocarcinoma: Endometrial (uterine) endometrioid carcinomas frequently express cytoplasmic vimentin, whereas most primary endocervical adenocarcinomas are vimentin-negative; combined interpretation with markers such as ER, p16, and CEA improves diagnostic accuracy. This difference has been repeatedly documented in comparative studies and series.
• Carcinosarcomas and sarcomatoid change: Vimentin highlights mesenchymal/sarcomatous components in mixed Müllerian tumors, aiding recognition of biphasic differentiation.
• Other gynecologic tumors: Vimentin expression is used alongside lineage markers (PAX8, CKs, desmin, SMA) to classify ambiguous or high-grade lesions. Recent multi-center pathology reviews reaffirm the role of IHC panels (including vimentin) in contemporary gynecologic tumor workups.

Utility in breast pathology

Vimentin is not a stand-alone diagnostic marker in routine breast carcinoma workups but is informative in specific contexts:

• Metaplastic (spindle cell) and sarcomatoid carcinomas: These tumors frequently show vimentin positivity in their mesenchymal components and vimentin assists in distinguishing metaplastic elements from pure epithelial patterns when used with cytokeratins and lineage markers.
• Basal-like / triple-negative phenotypes and EMT features: Studies link vimentin expression with EMT features, higher grade, and basal-like profiles in subsets of breast cancers, making it useful for research and selected diagnostic panels.

Key features of CE/IVD-validated Anti-Vimentin IHC antibodies

• Validated for FFPE tissue and routine histopathology workflows.
• High analytical sensitivity and specificity for vimentin protein detection when tested against standard positive/negative controls.
• Reproducible staining patterns across laboratories when used within recommended protocols (antigen retrieval, dilution, and detection systems).
• Suitable for multiplex panels (used together with cytokeratins, PAX8, ER/PR, p16, CEA, desmin etc.) for lineage determination.
• Useful as a quality control marker for stromal/mesenchymal elements in tissue sections.